

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

August 06, 2012

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Kind Attn.: Mr. K. K. Mishra

Dear Sirs

Re.: Unaudited financial results for the quarter ended on June 30, 2012.

We are forwarding herewith unaudited financial results for the quarter ended on June 30, 2012 reviewed by Audit Committee and taken on record by the Board of Directors on August 06, 2012 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully
For **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

PART I
Unaudited (Provisional) Financial Results for the Quarter ended June 30, 2012.

Rupees in Lacs				Sr. No.	Particulars	Rupees in Lacs			
CONSOLIDATED						COMPANY			
3 Months ended 30/06/2012 (Unaudited)	Preceding 3 months ended 31/03/2012 (Audited)	Corresponding 3 months ended 30/06/2011 in the previous year (Unaudited)	Previous year ended 31/03/2012 (Audited)			3 Months ended 30/06/2012 (Unaudited)	Preceding 3 months ended 31/03/2012 (Audited)	Corresponding 3 months ended 30/06/2011 in the previous year (Unaudited)	Previous year ended 31/03/2012 (Audited)
154,664	137,926	118,890	518,067	1	Income from operations	62,071	60,559	57,666	245,650
3,054	3,490	1,539	9,070	i	Gross Sales	1,122	1,273	975	4,325
151,610	134,436	117,351	508,997	ii	Less: Excise Duty	60,949	59,286	56,691	241,325
7,832	5,364	7,218	17,334	a	Net Sales	20,993	19,092	21,496	73,753
159,442	139,800	124,569	526,331	b	Other operating income	81,942	78,378	78,187	315,078
				c	Total income from operations (net)				
31,201	34,475	26,481	118,894	2	Expenses	17,434	22,532	18,410	79,094
18,281	11,117	16,029	67,852	a	Cost of materials consumed	4,390	5,226	6,141	30,455
3,034	1,884	(6,307)	(18,811)	b	Purchases of stock-in-trade	3,706	31	(1,014)	(5,849)
22,976	19,805	16,923	75,122	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	12,705	10,830	10,544	43,455
4,343	3,908	3,472	15,788	d	Employee benefits expense	2,752	2,886	2,497	10,823
49,389	44,238	41,204	174,888	e	Depreciation and amortisation expense	24,615	21,595	25,064	101,145
				f	Other expenses	65,602	63,100	61,642	259,123
129,224	115,427	97,802	433,733	g	Total expenses	16,340	15,278	16,545	55,955
30,218	24,373	26,767	92,598	3	Profit/ (Loss) from Operations before other income, finance costs and exceptional Items (1-2)	269	1,208	865	23,914
951	1,758	631	5,315	4	Other income	16,609	16,486	17,410	79,869
31,169	26,131	27,398	97,913	5	Profit/ (Loss) from ordinary activities before finance costs and exceptional Items (3+4)	2,689	1,735	687	12,826
4,539	3,754	1,115	18,490	6	Finance costs	13,920	14,751	16,723	67,043
26,630	22,377	26,283	79,423	7	Profit/ (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	0	0	0	0
0	0	0	0	8	Exceptional items	13,920	14,751	16,723	67,043
26,630	22,377	26,283	79,423	9	Profit/ (Loss) from ordinary activities before tax (7+8)	650	811	1,430	1,291
6,537	4,363	2,854	11,304	10	Tax expense	13,270	13,940	15,293	65,752
20,093	18,014	23,429	68,119	11	Net Profit/ (Loss) from ordinary activities after tax (9-10)	0	0	0	0
0	0	0	0	12	Extraordinary items (net of tax expense)	13,270	13,940	15,293	65,752
20,093	18,014	23,429	68,119	13	Net Profit/ (Loss) for the period (11-12)	0	0	0	0
0	0	0	0	14	Share of profit/ (loss) of associates	0	0	0	0
(614)	(926)	(447)	(2,860)	15	Minority interest	13,270	13,940	15,293	65,752
19,479	17,088	22,982	65,259	16	Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)				
10,237	10,237	10,237	10,237	17	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237
			247,122	18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				244,695
				19 i	Earnings per share (before extraordinary items) (of Rs. 5/- each) (not annualised):				
9.51	8.35	11.22	31.87	a	Basic (Rs.)	6.48	6.81	7.47	32.11
9.51	8.35	11.22	31.87	b	Diluted (Rs.)	6.48	6.81	7.47	32.11
				19 ii	Earnings per share (after extraordinary items) (of Rs. 5/- each) (not annualised):				
9.51	8.35	11.22	31.87	a	Basic (Rs.)	6.48	6.81	7.47	32.11
9.51	8.35	11.22	31.87	b	Diluted (Rs.)	6.48	6.81	7.47	32.11

Notes :

- The above results for the quarter ended on June 30, 2012 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 6, 2012.
- The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Clause 41 of the Listing Agreement.
- The change in Investments during the quarter is as under:
Zydus BSV Pharma Private Limited (Additional Investment) - Rs. 150 Lacs
- The above financial results include loss on account of foreign exchange fluctuations of Rs. 837 Lacs for the quarter [gain of Rs. 915 Lacs in the corresponding quarter of previous year] on standalone basis and Rs. 1,155 Lacs for the quarter [gain of Rs. 1,552 Lacs in the corresponding quarter of previous year] on consolidated basis.
- Previous year figures have been regrouped/ reclassified wherever necessary to correspond with the current reporting period.
- The Company has one segment of activity viz., "Pharmaceuticals".

PART II
Select Information for the Quarter Ended 30/06/2012

3 Months ended 30/06/2012	Preceding 3 months ended 31/03/2012	Corresponding 3 months ended 30/06/2011 in the previous year	Previous year ended 31/03/2012	Particulars	3 Months ended 30/06/2012	Preceding 3 months ended 31/03/2012	Corresponding 3 months ended 30/06/2011 in the previous year	Previous year ended 31/03/2012
51,610,474	51,610,474	51,610,474	51,610,474	A	51,610,474	51,610,474	51,610,474	51,610,474
25.21%	25.21%	25.21%	25.21%	1	25.21%	25.21%	25.21%	25.21%
				PARTICULARS OF SHAREHOLDING				
				Public shareholding				
				- Number of shares				
				- Percentage of Shareholding				
				2				
				Promoters and Promoter Group Shareholding				
				a				
				Pledged / Encumbered				
				- Number of shares				
				- Percentage of shares (as a % of the total shareholding of promoter and promoter group)				
				- Percentage of shares (as a % of the total share capital of the company)				
				b				
				Non - encumbered				
				- Number of shares				
				- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)				
				- Percentage of shares (as a % of the total share capital of the company)				
153,138,046	153,138,046	153,138,046	153,138,046		153,138,046	153,138,046	153,138,046	153,138,046
100%	100%	100%	100%		100%	100.00%	100.00%	100.00%
74.79%	74.79%	74.79%	74.79%		74.79%	74.79%	74.79%	74.79%

Particulars	3 months ended 30/06/2012
B	
INVESTOR COMPLAINTS [In Numbers]	
Pending at the beginning of the quarter	Nil
Received during the quarter	19
Disposed of during the quarter	19
Remaining unresolved at the end of the quarter	Nil

For Cadila Healthcare Limited,


Pankaj R. Patel
Chairman & Managing Director